CoChat

Vitamin K to prevent fractures in older women: systematic review and economic evaluation

Open access
Stevenson, M, Lloyd-Jones, M, Papaioannou, D · 2009 · Health Technology Assessment

The DOI matches its Crossref record; 264 of the 275 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: To determine the clinical and cost-effectiveness of vitamin K in preventing osteoporotic fractures in postmenopausal women. DATA SOURCES: Searches were conducted in May 2007 in MEDLINE, MEDLINE In-Process, EMBASE, Cochrane Database of Systematic Reviews, Cochrane Controlled Trials Register, BIOSIS, CINAHL, DARE, NHS EED and HTA databases, AMED, NRR, Science Citation Index and Current Controlled Trials. The MEDLINE search was updated in March 2009. REVIEW METHODS: Selected studies were assessed and subjected to data extraction and quality assessment using standard methods. Where appropriate, meta-analysis was carried out. A mathematical model was constructed to estimate the cost-effectiveness of vitamin K1. RESULTS: The electronic literature searches identified 1078 potentially relevant articles. Of these, 14 articles relating to five trials that compared vitamin K with a relevant comparator in postmenopausal women with osteoporosis or osteopenia met the review inclusion criteria. The double-blind ECKO trial compared 5 mg of phylloquinone (vitamin K1) with placebo in Canadian women with osteopenia but without osteoporosis. Four open-label trials used 45 mg of menatetrenone (vitamin K2) in Japanese women with osteoporosis; the comparators were no treatment, etidronate or calcium. The methodological quality of the ECKO trial was good; however, all four menatetrenone trials were poorly reported and three were very small (n < 100 in each group). Phylloquinone was associated with a statistically significant reduction in the risk of clinical fractures relative to placebo [relative risk 0.46, 95% confidence interval (CI) 0.22 to 0.99]; morphometric vertebral fractures were not reported. The smaller menatetrenone trials found that menatetrenone was associated with a reduced risk of morphometric vertebral fractures relative to no treatment or calcium; however, the larger Osteoporosis Fracture (OF) study found no evidence of a reduction in vertebral fracture risk. The three smaller trials found no significant difference between treatment groups in non-vertebral fracture incidence. In the ECKO trial, phylloquinone was not associated with an increase in adverse events. In the menatetrenone trials, adverse event reporting was generally poor; however, in the OF study, menatetrenone was associated with a significantly higher incidence of skin and skin appendage lesions. No published economic evaluations of vitamin K were found and a mathematical model was thus constructed to estimate the cost-effectiveness of vitamin K1. Comparators were alendronate, risedronate and strontium ranelate. Vitamin K1 and alendronate were markedly more cost-effective than either risedronate or strontium ranelate. The base-case results favoured vitamin K1, but this relied on many assumptions, particularly on the efficacy of preventing hip and vertebral fractures. Calculation of the expected value of sampled information was conducted assuming a randomised controlled trial of 5 years' duration comparing alendronate with vitamin K1. The costs incurred in obtaining updated efficacy data from a trial with 2000 women per arm were estimated to be a cost-effective use of resources. CONCLUSIONS: There is currently large uncertainty over whether vitamin K1 is more cost-effective than alendronate; further research is required. It is unlikely that the present prescribing policy (i.e. alendronate as first-line treatment) would be altered.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3310/hta13450

Cites

264 of 264 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Part of this paper’s reference list could not be split into single entries.

1 retracted

Items 201–264 of 264

Research works printed but not linked: 15

  1. Torgerson DJ, Dolan P. The cost of treating osteoporotic fractures in the United Kingdom female population -the author replies. Osteoporos Int 2000;11:551-2.
  2. Johnell O, Kanis JA, Oden A, Johansson H, De Laet C, Delams P, et al. Predictive value of bone mineral density for hip and other fractures. J Bone Miner Res 2005;20:1185-94.
  3. Duggan P, Cashman KD, Flynn A, Bolton-Smith C, Kiely M. Phylloquinone (vitamin K-1) intakes and food sources in 18-year-old to 64-year-old Irish adults. Br J Nutr 2004;92:151-8.
  4. Compston JE. Boning up on vitamin K - commentary. Gut 2001;48:448.
  5. Fairfield KM, Fletcher RH. Vitamins for chronic disease prevention in adults: scientific review [erratum appears in JAMA 2002;288:1720]. JAMA 2002;287:3116-26.
  6. Cambridge Laboratories. Menadiol diphosphate tablets 10mg. 2002. URL: http://emc.medicines.org.uk/.
  7. National Osteoporosis Foundation Working Group on Vertebral Fractures. Assessing vertebral fractures. J Bone Miner Res 1995;10:518-523.
  8. Genant HK, Jergas M. Assessment of prevalent and incident fractures in osteoporosis research. Osteoporos Int 2003;14:S43-S55.
  9. Cranney A, Tugwell P, Wells G, Guyatt G. Systematic reviews of randomized trials in osteoporosis: introduction and methodology. Endocr Rev 2002;23:497-507.
  10. Insull W, Troendle A, Silvers A, Dunne CW. Substantial non-compliance to dose and time prescriptions for medications treating hypercholesterolaemia. Atherosclerosis 1995;115:S93.
  11. Stephenson BJ, Rowe BH, Haynes RB, Macharia WM, Leon G. Is this patient taking the treatment as prescribed? JAMA 1993;269:2779-81.
  12. Howell N, Trotter R, Mottram DR, Rowe PH. Compliance with statins in primary care. Pharm J 2004;272:23-6.
  13. Cochrane Review Manager 4.2.7. Oxford: The Cochrane Collaboration; 2004. URL: http://ims. cochrane.org/revman/.
  14. Shiraki M. Vitamin K2 effects on the risk of fractures and on lumbar bone mineral density in osteoporosis -a randomized prospective open-label 3-year study. Osteoporos Int 2002;13:S160.
  15. Eisai Co. Ltd. Eisai announces the intermediate analysis of anti-osteoporosis treatment post-marketing research to investigate the benefits of menatetrenone as part of the Ministry of Health, Labour and Welfare's Pharmacoepidemiological Drug Review Program. 2005. URL: www.eisai.co.jp/enews/.

Cited by

See all 90

Metadata

Authors
Stevenson, M., Lloyd-Jones, M., & Papaioannou, D.
Affiliations
University of Southampton (GB)
Corresponding author
Stevenson, M
Venue
Health Technology Assessment
Published
2009-09
Volume
13
Issue
45
Pages
iii-xi, 1
ISSN
  • 1366-5278 (ISSN-L)
  • 2046-4924
OpenAlex
W2158674987
Cited by
90
References
275
Citations by year
2026: 1 · 2025: 1 · 2024: 3 · 2023: 1 · 2022: 3 · 2021: 2 · 2020: 1 · 2019: 3 · 2018: 6 · 2017: 5 · 2016: 15 · 2015: 6 · 2014: 18 · 2013: 8 · 2012: 9
FWCI
0.65
Type
journal article
Language
en
Open access
Locations
  • Health Technology Assessment (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Health Technology Assessment programme (07/16/01)
Topics
  • Health Sciences › Nursing › Nutrition and Dietetics › Vitamin K Research Studies
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Vitamin D Research Studies
Keywords
vitamin K, osteoporotic fractures, postmenopausal women, vitamin K1, menatetrenone, fracture prevention, cost-effectiveness, vertebral fractures, non-vertebral fractures, osteopenia, osteoporosis, adverse events, economic evaluation model
MeSH terms
Aged, Aged, 80 and over, Cost-Benefit Analysis, Female, Humans, Vitamin K 1, Vitamin K, Vitamins, Osteoporosis, Postmenopausal, Models, Econometric, Quality-Adjusted Life Years, Vitamin K 2, Bone Density Conservation Agents, Fractures, Bone

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.